ArticleBMC gastroenterology2026

Comparative efficacy and safety of subcutaneous vedolizumab versus other targeted inflammatory bowel therapies in patients with moderate to severe ulcerative colitis: a network meta-analysis update.

Jeanne Jiang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.